Adjuvant chemotherapy for completely resected non-small-cell lung cancer

Acta Medica Okayama

Volumn 63, Issue 5, 2009, Pages 223-230

  Suehis, Hiroshi ^a,b   Toyooka, Shinichi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Adjuvant chemotherapy; Cisplatin; Lung cancer; Non small cell lung cancer; Uracil tegafur

Indexed keywords

ANTINEOPLASTIC AGENT; TEGAFUR; URACIL;

ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS (TOPIC); PATHOLOGY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 74349117245     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin (2006) 56: 106-130.
2. Travis WD, Colby TV, Corrin B, Shimosato Y and Brambilla E; in Collaboration with Sobin LH and Pathologists from 14 Countries: World Health Organization International Histological Classification of Tumors, Histological Typing of Lung and Pleural Tumors, 3rd Ed, Springer-Verlag, Berlin (1999)
3. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest (1997) 111: 1710-1717.
4. van Rens MT, de la Riviere AB, Elbers HR and van Den Bosch JM: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest (2000) 117: 374-379.
5. Fang D, Zhang D, Huang G, Zhang R, Wang Land Zhang D: Results of surgical resection of patients with primary lung cancer: a retro spective analysis of 1,905 cases. Ann Thorac Surg (2001) 72: 1155-1159.
6. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T and Miyaoka E: Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer (2005) 50: 227-234.
7. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T and Miyaoka E: A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol (2008) 3: 46-52.
8. Holmes EC and Gail M: Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol (1986)4: 710-715.
9. Niiranen A, Niitamo-Korhonen S, Kouri M, Assendelft A, Mattson K and Pyrhonen S: Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol (1992) 10: 1927-1932.
10. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ (1995)311: 899-909.
11. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F and Tonato M: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 95: 1453-1461.
12. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, Rudd RM and Spiro SG: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg (2004) 26: 173-182.
13. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 350: 351-360.
14. Chevalier TL, Dunant A, Arriagada R, Bergman B, Chabowski M, LePechoux C, Kozlowski M, Tarayre M and Pignon JP and IALT Collaborative Group: Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol (2008) 26: 398s (suppl; abstr 7507).
15. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T and Shepherd F: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005)352: 2589-2597.
16. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE and Green MR: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol (2008)26: 5043-5051.
17. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M and Hurteloup P: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol (2006) 7: 719-727.
18. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D and Chevalier TL: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 26: 3552-3559.
19. Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti GV, Douillard JY, Spiro S and Shepherd FA: Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol (2008) 26: 3573-3581.
20. Stewart LA, Burdett S, Tierney JF and Pignon J, on behalf of the NSCLC Collaborative Group: Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol (2007) 25: 397s (suppl; abstr 7552).
21. Wada H, Hitomi S and Teramatsu T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol (1996) 14: 1048-1054.
22. Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, Kawamura M, Kondo T, Koike K, Handa M, Kanno R and Fujimura S: A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer (2003) 40: 181-186.
23. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med (2004) 350: 1713-1721.
24. Imaizumi M: Postoperative adjuvant cisplatin, vindesine, plus ura cil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer (2005)49: 85-94.
25. Nakagawa M, Tanaka F, Tsubota N, Ohta M, Takao M and Wada H: A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann Oncol (2005) 16: 75-80.
26. Nakagawa K, Tada H, Akashi A, Yasumitsu T, Iuchi K, Taki T and Kodama K: Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer (2006) 95: 817-821.
27. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M and Wada H: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol (2005) 23: 4999-5006.
28. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Chevalier TL and Soria JC: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 355: 983-991.
29. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350: 2129-2139.
30. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene predict prolonged sur vival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol (2005) 23: 2513-2520.
31. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304: 1497-1500.
32. Suehisa H, Toyooka S, Hotta K, Uchida A, Soh J, Fujiwara Y, Matsuo K, Ouchida M, Takata M, Kiura K and Date H: Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol (2007) 25: 3952-3597.